Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials

Canadian Journal of Cardiology

Volumn 29, Issue 12, 2013, Pages 1704-1711

  Grandi, Sonia M ^a,d   Shimony, Avi ^a,b   Eisenberg, Mark J ^a,c,d  

^a MCGILL UNIVERSITY   (Canada)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; META ANALYSIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING CESSATION; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; TREATMENT DURATION;

ACUTE CORONARY SYNDROME; ADULT; AGED; BUPROPION; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION;

EID: 84888220542     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.09.014     Document Type: Review

References (28)

1. Lloyd-Jones D.M., Hong Y., Labarthe D., et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation 2010, 121:586-613.
2. Critchley J., Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2003, CD003041.
3. Colivicchi F., Mocini D., Tubaro M., Aiello A., Clavario P., Santini M. Effect of smoking relapse on outcome after acute coronary syndromes. Am J Cardiol 2011, 108:804-808.
4. Wilson K., Gibson N., Willan A., Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000, 160:939-944.
5. Rea T.D., Heckbert S.R., Kaplan R.C., et al. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 2002, 137:494-500.
6. Fiore M.C., Jaén C.R., Baker T.B., et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline April 2009, US Department of Health and Human Services, Public Health Service.
7. Singh S., Loke Y.K., Spangler J.G., Furberg C.D. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011, 183:1359-1366.
8. Prochaska J.J., Hilton J.F. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012, 344:e2856.
9. Ludvig J., Miner B., Eisenberg M.J. Smoking cessation in patients with coronary artery disease. Am Heart J 2005, 149:565-572.
10. Tonstad S., Farsang C., Klaene G., et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003, 24:946-955.
11. Product Monograph: Champix®, May 2013. Pfizer Canada Inc. Available at: Accessed October 3,2013. http://www.pfizer.ca/en/our_products/products/monograph/152.
12. Prescribing information: Wellbutrin®, March 2013. GlaxoSmithKline, Research Triangle, NC. Available at: Accessed October 3,2013. http://us.gsk.com/products/assets/us_wellbutrin_tablets.pdf.
13. Eisenberg M.J., Filion K.B., Yavin D., et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008, 179:135-144.
14. Rigotti N.A., Thorndike A.N., Regan S., et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med 2006, 119:1080-1087.
15. Planer D., Lev I., Elitzur Y., et al. Bupropion for smoking cessation in patients with acute coronary syndrome. Arch Intern Med 2011, 171:1055-1060.
16. Eisenberg M.J., Grandi S.M., Gervais A., et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. JAm Coll Cardiol 2013, 61:524-532.
17. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151:W65-W94.
18. Higgins PT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. The Cochrane Collaboration, March 2011. Available at: Accessed October 3,2013. http://www.cochrane-handbook.org.
19. McBride C.M., Emmons K.M., Lipkus I.M. Understanding the potential of teachable moments: the case of smoking cessation. Health Educ Res 2003, 18:156-170.
20. Rigotti N.A., Munafo M.R., Stead L.F. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev 2007, 2:CD001837.
21. Campbell I.A., Prescott R.J., Tjeder-Burton S.M. Smoking cessation in hospital patients given repeated advice plus nicotine or placebo chewing gum. Respir Med 1991, 85:155-157.
22. Rigotti N.A., Pipe A.L., Benowitz N.L., et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010, 121:221-229.
23. Joseph A.M., Norman S.M., Ferry L.H., et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. NEngl J Med 1996, 335:1792-1798.
24. Rigotti N.A., Munafo M.R., Stead L.F. Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med 2008, 168:1950-1960.
25. Benowitz N.L., Peyton J., Ahijevych K., et al. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002, 4:149-159.
26. Jorenby D.E., Hays J.T., Rigotti N.A., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56-63.
27. Jorenby D.E., Leischow S.J., Nides M.A., et al. Acontrolled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. NEngl J Med 1999, 340:685-691.
28. Gonzales D., Rennard S.I., Nides M., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.